Details checkedClinical trial listing onlyCheckedregistry

Beijing PAP plus Medication Study in ISSHL with Obstructive Sleep Apnea

Also known as: Methylprednisolone Hemisuccinate, non-invasive positive airway pressure, Ginaton, The Effect of PAP on ISSHL Comorbided With OSA, NCT04192656

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Procedure/Rehab

Modality

Procedure/Rehab

Stage

Phase 4

Status

Active

Target Gene

—

Route / Mode

Positive airway pressure plus medication

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

China

Population

adult, sudden, sleep-apnea

Trial IDs

Mechanism

Recruiting Phase 4 study evaluating positive airway pressure added to standard medication, including methylprednisolone hemisuccinate and Ginaton, in idiopathic sudden sensorineural hearing loss with obstructive sleep apnea.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Corrected from a standalone methylprednisolone row to the actual PAP-plus-medication study. Methylprednisolone and Ginaton are medication components in both arms; the differentiating intervention is positive airway pressure.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT04192656

Open

Key Events

2019-11-01

Registry lists actual start for PAP plus medication study in ISSHL with obstructive sleep apnea

Clinical Trials (1)

NCT04192656

Data Checks